Authors:
VAHDAT L
WONG ET
WILE MJ
ROSENBLUM M
FOLEY KM
WARRELL RP
Citation: L. Vahdat et al., THERAPEUTIC AND NEUROTOXIC EFFECTS OF 2-CHLORODEOXYADENOSINE IN ADULTS WITH ACUTE MYELOID-LEUKEMIA, Blood, 84(10), 1994, pp. 3429-3434
Authors:
RIGAS JR
FRANCIS PA
MUINDI JRF
KRIS MG
HUSELTON C
DEGRAZIA F
ORAZEM JP
YOUNG CW
WARRELL RP
Citation: Jr. Rigas et al., CONSTITUTIVE VARIABILITY IN THE PHARMACOKINETICS OF THE NATURAL RETINOID, ALL-TRANS-RETINOIC ACID, AND ITS MODULATION BY KETOCONAZOLE, Journal of the National Cancer Institute, 85(23), 1993, pp. 1921-1926
Authors:
NUSSBAUM SR
WARRELL RP
RUDE R
GLUSMAN J
BILEZIKIAN JP
STEWART AF
STEPANAVAGE M
SACCO JF
AVERBUCH SD
GERTZ BJ
Citation: Sr. Nussbaum et al., DOSE-RESPONSE STUDY OF ALENDRONATE SODIUM FOR THE TREATMENT OF CANCER-ASSOCIATED HYPERCALCEMIA, Journal of clinical oncology, 11(8), 1993, pp. 1618-1623
Authors:
WARRELL RP
LOVETT D
DILMANIAN FA
SCHNEIDER R
HEELAN RT
Citation: Rp. Warrell et al., LOW-DOSE GALLIUM NITRATE FOR PREVENTION OF OSTEOLYSIS IN MYELOMA - RESULTS OF A PILOT RANDOMIZED STUDY, Journal of clinical oncology, 11(12), 1993, pp. 2443-2450
Citation: Jf. Muindi et al., INVITRO DIFFERENTIAL METABOLISM OF MERBARONE BY XANTHINE-OXIDASE AND MICROSOMAL FLAVOENZYMES - THE ROLE OF REACTIVE OXYGEN SPECIES, Drug metabolism and disposition, 21(3), 1993, pp. 410-414
Citation: Rp. Warrell, RETINOID RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA - NEW MECHANISMS,STRATEGIES, AND IMPLICATIONS, Blood, 82(7), 1993, pp. 1949-1953
Authors:
MILLER WH
LEVINE K
DEBLASIO A
FRANKEL SR
DMITROVSKY E
WARRELL RP
Citation: Wh. Miller et al., DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIABY A REVERSE TRANSCRIPTION-POLYMERASE CHAIN-REACTION ASSAY FOR THE PML RAR-ALPHA FUSION MESSENGER-RNA, Blood, 82(6), 1993, pp. 1689-1694
Citation: L. Vahdat et Rp. Warrell, TREATMENT OF ACUTE MYELOBLASTIC-LEUKEMIA IN ADULTS WITH 2-CHLORO-DEOXYADENOSINE, Blood, 82(10), 1993, pp. 10000129-10000129
Citation: L. Vadhat et al., LEUKOCYTOSIS, THE RETINOIC ACID (RA) SYNDROME, AND EARLY MORTALITY INACUTE PROMYELOCYTIC LEUKEMIA (APL) - WHEN IS CHEMOTHERAPY NEEDED DURING REMISSION INDUCTION WITH ALL-TRANS RA, Blood, 82(10), 1993, pp. 10000192-10000192
Authors:
JURCIC JG
CARON PC
MILLER WH
YAO TJ
MASLAK P
FINN R
LARSON SM
WARRELL RP
SCHEINBERG DA
Citation: Jg. Jurcic et al., I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA), Blood, 82(10), 1993, pp. 10000193-10000193
Authors:
XIAO YH
MILLER WH
WARRELL RP
DMITROVSKY E
ZELENETZ AD
Citation: Yh. Xiao et al., PULSED-FIELD GEL-ELECTROPHORESIS ANALYSIS OF RETINOIC ACID RECEPTOR-ALPHA AND PROMYELOCYTIC LEUKEMIA REARRANGEMENTS - DETECTION OF THE T(1517) TRANSLOCATION IN THE DIAGNOSIS OF ACUTE PROMYELOCYTIC LEUKEMIA, The American journal of pathology, 143(5), 1993, pp. 1301-1311
Authors:
MILLER WH
KAKIZUKA A
FRANKEL SR
WARRELL RP
DEBLASIO A
LEVINE K
EVANS RM
DMITROVSKY E
Citation: Wh. Miller et al., REVERSE TRANSCRIPTION POLYMERASE CHAIN-REACTION FOR THE REARRANGED RETINOIC ACID RECEPTOR-ALPHA CLARIFIES DIAGNOSIS AND DETECTS MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA, Proceedings of the National Academy of Sciences of the United Statesof America, 89(7), 1992, pp. 2694-2698